![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel | Konferenzbeitrag
Anzahl der Publikationen: 10
Zeitschriftenartikel
Müller, Rüdiger B.; Schulze-Koops, Hendrik; Furst, Daniel E.; Cohen, Stanley B.; Kwok, Kenneth; Wang, Lisy; Killeen, Tim und Kempis, Johannes von
(2022):
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
In: Clinical Rheumatology, Bd. 41, Nr. 4: S. 1045-1055
Müller, Rüdiger B.; Hasler, Caroline; Popp, Florian; Mattow, Frederik; Durmisi, Mirsada; Souza, Alexander; Hasler, Paul; Rubbert-Roth, Andrea; Schulze-Koops, Hendrik und Kempis, Johannes von
(2019):
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.
In: Journal of Clinical Medicine, Bd. 8, Nr. 10, 1548
Müller, Rüdiger B.; Späth, Michael; Restorff, Cord von; Ackermann, Christoph; Schulze-Koops, Hendrik und Kempis, Johannes von
(2019):
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.
In: Journal of Clinical Medicine, Bd. 8, Nr. 3, 302
Kempis, Johannes von; Duetsch, Sabine; Reuschling, Nicola; Villiger, Rahel; Villiger, Peter M.; Vallelian, Florencee; Schär, Dominik J. und Müller, Rüdiger B.
(2019):
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
In: Swiss Medical Weekly, Bd. 149, w20022
Heinimann, Katja; Kempis, Johannes von; Sauter, Rafael; Schiff, Michael; Sokka-Isler, Tuulikki; Schulze-Koops, Hendrik und Müller, Rüdiger
(2018):
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort.
In: Journal of Clinical Medicine, Bd. 7, Nr. 3, 57
[PDF, 941kB]
Müller, Rüdiger; Grunke, Mathias; Wendler, Jörg; Schuch, Florian; Hofmann-Preiss, Karina; Boettger, Ina; Jakobs, Rüdiger; Schulze-Koops, Hendrik und Kempis, Johannes von
(2018):
The Value of an Automated Ultrasound System in the Detection of Synovitis.
In: Ultrasound International Open, Bd. 4, Nr. 2, E61-E67
[PDF, 695kB]
Müller, Rüdiger B.; Reshiti, Nazim; Kägi, Toni; Finckh, Axel; Haile, Sarah R.; Schulze-Koops, Hendrik; Schiff, Michael; Späth, Michael und Kempis, Johannes von
(2017):
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
In: Clinical Rheumatology, Bd. 36, Nr. 1: S. 59-66
Müller, Rüdiger; Schulze-Koops, Hendrik; Furst, Daniel E.; Cohen, Stanley B.; Kwok, Kenneth; Maniccia, Anna; Wang, Lisy; Akylbekova, Ermeg und Kempis, Johannes von
(2017):
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies.
In: Arthritis & Rheumatology, Bd. 69
Müller, Rüdiger; Thalmann, Reto; Schulze-Koops, Hendrik; Graf, Nicole und Kempis, Johannes von
(2017):
Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort.
In: Arthritis & Rheumatology, Bd. 69
Konferenzbeitrag
Müller, Rüdiger; Grunke, Mathias; Wendler, J.; Schuch, F.; Hofmann-Preiss, Karina; Boettger, I.; Jakobs, R.; Schulze-Koops, Hendrik und Kempis, Johannes von
(2014):
The Value of an Automated Ultrasound System in the Detection of Synovitis.
EULAR 2014, Paris, 11-14 June 2014.
Annals of the rheumatic diseases.
Bd. 73, Nr. Suppl. 2
BMJ Publishing Group. S. 1136
[PDF, 55kB]